伊贝沙坦对早期糖尿病肾病大鼠血浆中AngⅡ浓度及t-PA和PAI-1活性的影响

Protective effect and mechanism of lrbesartan on angiotensin Ⅱ plasminogen activator and plasminogen activator inhibitor type 1 in diabetic nephropathy rats

目的 探讨早期糖尿病肾病大鼠血浆血管紧张素Ⅱ (AngⅡ )浓度及组织型纤溶酶原激活物 (t PA)和纤溶酶原激活物抑制剂 (PAI 1)的活性变化及血管紧张素Ⅱ受体 (ART)拮抗剂伊贝沙坦对其的影响。方法 雄性Wistar大鼠随机分为正常对照组 (A)、糖尿病肾病组 (B)、伊贝沙坦治疗组 (C)。自造模始第 5周起C组每天给予伊贝沙坦 10mg/kg ,A、B、C 3组每周测 1次血糖 ,并于第 5周始 ,第 12周末取血测AngⅡ浓度 ,t PA及PAI 1活性并留 2 4h尿测尿白蛋白 (UAIb)及 β2 微球蛋白 (Uβ2 MG)。结果 第 5周始 ,B、C两组 2 4hUAIb和Uβ2 MG含量 ,血PAI 1活性、AngⅡ浓度均明显升高 ,血t PA活性降低 ,与A组比较有统计学意义 ;第 12周末 ,C组t PA活性较用药前明显升高 ,UAIb、Uβ2 MG含量以及PAI 1活性较用药前明显降低 ,与用药前比较有统计学意义。结论 早期糖尿病肾病大鼠血浆t PA、PAI 1活性出现异常 ,伊贝沙坦能明显改善这种病理变化 ,对糖尿病大鼠肾脏有一定的保护作用。

Objective To investigate the changes in angiotensin Ⅱ(AngⅡ) plasminogen activator(t-PA),plasminogen activator inhibitor type 1(PLA-1) and the effects of Irbesartan in diabetic nephropathy rats.Methods Male wistar rats were randomly divided into normal control group(A),diabetic nephropathy control group(B),diabetic nephropathy group(C) treated with Irbesartan(10mg·kg -1 ·d -1 ) which were administered at the beginning of 5 weeks. Blood glucose was measured every week and AngⅡ,t-PA,PIA-1 were measured respectively at the beginning of 5 weeks and at the end of 12 weeks.Results There was obvious difference in UALb,Uβ 2-MG,PAI-1,AngⅡ,t-PA between B,C and A group. Moreover,there was obvious difference in t-PA,PAI-1,Uβ 2-MG,UAlb between C and C which was not be treated as well.Conclusion Irbesartan could protect the nephropathy of diabetic rats.